MergerLinks - ZQ Capital to acquire Allergy Therapeutics for £48m.

Announced

16 Oct 2023

ZQ Capital to acquire Allergy Therapeutics for £48m.

Synopsis

ZQ Capital, an investment firm, offered to acquire Allergy Therapeutics, a specialty pharmaceutical company focused upon the diagnosis and treatment of allergy, for £48m.

Principals

target

Allergy Therapeutics

bidder

Zq Capital

Show Details & Financials

Market Context

Sort

Manuel Llobet

ManagerCEO at ALLERGY THERAPEUTICS

Shaun Furlong

ManagerCFO at ALLERGY THERAPEUTICS

Emma Earl

Financial AdvisorManaging Director at Panmure Gordon & Co

Mark Rogers

Financial AdvisorAssociate at Panmure Gordon & Co

Freddy Crossley

Financial AdvisorHead of Healthcare at Panmure Gordon & Co

Rupert Dearden

Financial AdvisorManaging Director at Panmure Gordon & Co

Alan Montgomery

LawyerPartner at Herbert Smith Freehills

Mark Bardell

LawyerPartner at Herbert Smith Freehills

Savannah van Dongen

LawyerAssociate at Herbert Smith Freehills

Zheqing (Simon) Shen

ManagerCEO at ZQ CAPITAL

Henrik Persson

Henrik Persson

Financial AdvisorHead of PLC Advisory at Cavendish Corporate Finance

Seamus Fricker

Financial AdvisorAssociate Director at Cavendish Corporate Finance

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

Register now Sign up with LinkedIn

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.